half-life is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Pan frying (sauté) on stove top heat: 120 °C (248 °F) Deep frying: 160–180 °C (320–356 °F) Oven baking: Average of 180 °C (356 °F) Smoke point decreases at a different pace in different oils. Considerably above the temperature of the smoke point is the flash point, the point at which the vapours from the oil can ignite in air, given an ignition source. The following table presents smoke points of various fats and oils.
The European bone skipper, Thyreophora cynophila, is an obligately necrophagous fly. It relies on carrion bone marrow in the first stage of its life cycle. Many other types of fly are facultatively necrophagous. Examples commonly found on land include blow flies, flesh flies, muscid flies, black soldier flies, ensign flies and thread-horns. Other necrophagous flies, for example black flies and lake flies, are semi-aquatic. Types of carrion fed upon include wildlife, livestock and poultry carcasses, slaughterhouse and fishing discards, and human bodies.
Carbetocin, sold under the brand names Pabal among others, is a medication used to prevent excessive bleeding after childbirth, particularly following Cesarean section. It appears to work as well as oxytocin. Due to it being less economical than other options, use is not recommended by NHS Scotland. It is given by injection into a vein or muscle. Side effects differ little from that of no treatment or placebo. Use is not recommended in people with epilepsy or eclampsia. Carbetocin is a manufactured long acting form of oxytocin. It works by activating the oxytocin receptor which causes the uterus to contract. Carbetocin was synthesized before 1971 at the Czechoslovak Institute of Organic Chemistry and Biochemistry and was first described by 1974. It was approved for medical use in Canada and the United Kingdom in 1997. It is on the World Health Organization's List of Essential Medicines. It is not available in the United States or Japan.
Hierarchies based on 'naturally' forming family, social and cultural traditions; 'Tight-knit' focus of activity/labor; Fraternal or nepotistic value systems; Personalized activity; including family rivalries, territorial disputes, recruitment and training of family members, etc.; Entrenched belief systems, reliance of tradition (including religion, family values, cultural expectations, class politics, gender roles, etc.); and, Communication and rule enforcement mechanisms dependent on organizational structure, social etiquette, history of criminal involvement, and collective decision-making.
Sources: en.wikipedia.org
Note: Other substances once thought to be vitamins were given B-numbers, but were disqualified once discovered to be either manufactured by the body or not essential for life. See § Related compounds for numbers 4, 8, 10, 11, and others.
Polypeptide toxins and many antibacterial peptides, such as colicins or hemolysins, and certain proteins involved in apoptosis, are sometimes considered a separate category. These proteins are water-soluble but can undergo significant conformational changes, form oligomeric complexes and associate irreversibly or reversibly with the lipid bilayer.
=== Energy and entropy === The microscopic features of liquids derive from an interplay between attractive intermolecular forces and entropic forces. The attractive forces tend to pull molecules close together, and along with short-range repulsive interactions, they are the dominant forces behind the regular structure of solids. The entropic forces are not "forces" in the mechanical sense; rather, they describe the tendency of a system to maximize its entropy at fixed energy (see microcanonical ensemble). Roughly speaking, entropic forces drive molecules apart from each other, maximizing the volume they occupy. Entropic forces dominant in gases and explain the tendency of gases to fill their containers. In liquids, by contrast, the intermolecular and entropic forces are comparable, so it is not possible to neglect one in favor of the other. Quantitatively, the binding energy between adjacent molecules is the same order of magnitude as the thermal energy
On 2 February, she met in Miraflores Palace with Delcy and Jorge Rodríguez to establish "the work agenda between the Bolivarian Republic of Venezuela and the United States." After the meeting, the US embassy shared on social media that Dogu met with the Venezuelan administration to "reiterate the three phases that US Secretary of State Marco Rubio had outlined for Venezuela: stabilization, economic recovery and reconciliation, and transition." Felix Plasencia was named as diplomatic representative of Venezuela to the United States. United States Energy Secretary Chris Wright arrived to Caracas on 11 February to make an assessment on Venezuela's oil industry. He met with Delcy Rodríguez in the presidential palace. Days before, Wright said he was expecting to "visit some of the nation's oil fields to see firsthand how President Trump's historic US-Venezuela Energy Deal is unleashing peace and prosperity." According to the Venezuelan information minister, they discussed a bilateral energy agenda. The last US Energy Secretary that visited Venezuela before that was Bill Richardson in 2001 under US president Bill Clinton. Dogu and Plasencia received a US shipment of six metric tons of medicine and medical supplies that arrived in Venezuela on 13 February. Dogu indicated it was "the first of many donations" that will arrive "in the coming days". Plasencia said that it was a "message of cooperation among two sovereign countries." When asked by reporters on 13 February, Trump said that he was "going to make a visit to Venezuela" but did not provide more details.
== Notable researchers == There are several researchers in nanochemistry that have been credited with the development of the field. Geoffrey A. Ozin, from the University of Toronto, is known as one of the "founding fathers of Nanochemistry" due to his four and a half decades of research on this subject. This research includes the study of matrix isolation laser Raman spectroscopy, naked metal clusters chemistry and photochemistry, nanoporous materials, hybrid nanomaterials, mesoscopic materials, and ultrathin inorganic nanowires. Another chemist who is also viewed as one of the nanochemistry's pioneers is Charles M. Lieber at Harvard University. He is known for his contributions to the development of nano-scale technologies, particularly in the field of biology and medicine. The technologies include nanowires, a new class of quasi-one-dimensional materials that have demonstrated superior electrical, optical, mechanical, and thermal properties and can be used potentially as biological sensors. Research under Lieber has delved into the use of nanowires mapping brain activity. Shimon Weiss, a professor at the University of California, Los Angeles, is known for his research of fluorescent semiconductor nanocrystals, a subclass of quantum dots, for biological labeling. Paul Alivisatos, from the University of California, Berkeley, is also notable for his research on the fabrication and use of nanocrystals. This research has the potential to develop insight into the mechanisms of small-scale particles such as the process of nucleation, cation exchange, and branching.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.